<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01050855</url>
  </required_header>
  <id_info>
    <org_study_id>08-005658</org_study_id>
    <secondary_id>CHP 894</secondary_id>
    <nct_id>NCT01050855</nct_id>
  </id_info>
  <brief_title>Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders</brief_title>
  <acronym>RIC</acronym>
  <official_title>Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Children's Hospital of Philadelphia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital of Philadelphia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II pilot study to evaluate engraftment and toxicity of patients with
      non-malignant diseases using a reduced intensity conditioning regimen in the setting of
      allogeneic transplant for non malignant diseases. Bone Marrow or cord blood will be
      acceptable as a stem cell source.

      Recently, reduced intensity conditioning (RIC) regimens have been used for both adult
      patients with leukemias and pediatric patients with non-malignant diseases. These regimens
      are better tolerated, resulting in less transplant related morbidity and mortality. Stable
      mixed chimerism, while insufficient for eradication of leukemias, may be sufficient to cure
      patients with non-malignant diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are two conditioning regimens in this protocol for children &gt;6 months. Alemtuzumab
      (Campath), Fludarabine and Melphalan are used. The regimens differ by the timing and dosing
      of Alemtuzumab (Campath). The two timings are distal and intermediate.

        -  Distal campath is initiated 22 days prior to the allogeneic transplant.

        -  Intermediate campath is initiated 14 days prior to allogeneic transplant.

      The conditioning regimen for children with immunodeficiencies &lt;6 months omits melphalan, and
      substitutes two days of busulfan. This regimen is successfully used in the UK, and has been
      successful in a 3 month old infant at CHOP who engrafted with a haploidentical donor.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment and Survival</measure>
    <time_frame>Post Transplant -100 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Non Malignant Diseases</condition>
  <condition>Immunodeficiencies</condition>
  <condition>Hemoglobinopathies</condition>
  <arm_group>
    <arm_group_label>RIC: Distal Campath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day Treatment
Day - 22 Inpatient: Alemtuzumab (Campath) test dose IV or SQ (subcutaneously) over 2 hours
Day - 21 to-19 Alemtuzumab IV/ SQ
Day - 7 to -3 Readmission to hospital Fludarabine IV
Day - 2 Melphalan IV
Day - 1 Begin cyclosporine infusion
Day 0 Transplant: Bone marrow or cord blood infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIC:Intermediate Campath</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day Treatment
Day - 14 to-10 Inpatient: Alemtuzumab (Campath) IV or SQ (subcutaneously)
Day - 7 to -3 Fludarabine IV
Day - 2 Melphalan 140 mg/m2 IV
Day - 1 Cyclosporine infusion starts
Day 0 Transplant: Bone marrow or cord blood infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RIC: Mini Busulfan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day Treatment
Day - 8 Alemtuzumab (Campath) IV or SQ (subcutaneously)
Day - 7 Alemtuzumab (Campath) IV or SQ (subcutaneously)
Day - 6 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV
Day - 5 Alemtuzumab (Campath) IV or SQ (subcutaneously) Busulfan IV Fludarabine IV
Day - 4 Alemtuzumab (Campath) IV or SQ (subcutaneously) Fludarabine IV
Day - 3 Fludarabine IV
Day - 2 Fludarabine IV Cyclosporine infusion
Day - 1 Rest
Day 0 Transplant: Bone marrow or cord blood infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIC: Distal Campath</intervention_name>
    <description>Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)</description>
    <arm_group_label>RIC: Distal Campath</arm_group_label>
    <other_name>Reduced Intensity Conditioning Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIC:Intermediate Campath</intervention_name>
    <description>Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)</description>
    <arm_group_label>RIC:Intermediate Campath</arm_group_label>
    <other_name>Reduced Intensity Conditioning Regimen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RIC: Mini Busulfan</intervention_name>
    <description>Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)</description>
    <arm_group_label>RIC: Mini Busulfan</arm_group_label>
    <other_name>Reduced Intensity Conditioning Regimen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt;6 months- 25 years

          2. Diseases eligible for Distal Alemtuzumab:

               -  Immunodysregulation polyendocrinopathy enteropathy X-linked (IPEX) syndrome

               -  Sickle cell disease

               -  Thalassemia major

               -  Bone marrow failure

          3. Diseases eligible for Intermediate Alemtuzumab

               -  Hemophagocytic lymphohistiocytosis other macrophage activation syndromes, severe
                  Langerhans histiocytosis

               -  Severe combined immune deficiency, adenosine deaminase deficiency, common
                  variable immunodeficiency

               -  Wiskott-Aldrich syndrome

          4. Organ criteria:

               -  Cardiac: Echocardiogram shortening fraction &gt;27%

               -  Renal: Serum creatinine less than 1.5 times the upper limit of normal for age

               -  Hepatic: liver function tests must be less than 5 times the upper limit of normal

          5. No active infections

        Exclusion criteria

        1. Uncontrolled bacterial, fungal or viral infections
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy J Bunin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital of Philadelphia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara McGlynn</last_name>
    <phone>215-590-1303</phone>
    <email>mcglynn@email.chop.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Hankins, RN</last_name>
    <phone>215-590-5168</phone>
    <email>hankinsp@email.chop.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara McGlynn</last_name>
      <phone>215-590-1303</phone>
      <email>mcglynn@email.chop.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Hankins, RN</last_name>
      <phone>215 590-5168</phone>
      <email>hankinsp@email.chop.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nancy J Bunin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 15, 2010</study_first_submitted>
  <study_first_submitted_qc>January 15, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2010</study_first_posted>
  <last_update_submitted>December 21, 2017</last_update_submitted>
  <last_update_submitted_qc>December 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-malignant diseases</keyword>
  <keyword>Immune deficiencies</keyword>
  <keyword>Hemoglobinopathies</keyword>
  <keyword>Reduced Intensity Conditioning(RIC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

